MX2020001732A - Tratamiento de las afecciones del sistema nervioso central. - Google Patents
Tratamiento de las afecciones del sistema nervioso central.Info
- Publication number
- MX2020001732A MX2020001732A MX2020001732A MX2020001732A MX2020001732A MX 2020001732 A MX2020001732 A MX 2020001732A MX 2020001732 A MX2020001732 A MX 2020001732A MX 2020001732 A MX2020001732 A MX 2020001732A MX 2020001732 A MX2020001732 A MX 2020001732A
- Authority
- MX
- Mexico
- Prior art keywords
- disorders
- treatment
- nervous system
- central nervous
- mammal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762553070P | 2017-08-31 | 2017-08-31 | |
| PCT/JP2018/032949 WO2019045121A1 (en) | 2017-08-31 | 2018-08-30 | TREATMENT OF CNS DISEASES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020001732A true MX2020001732A (es) | 2020-03-20 |
Family
ID=63722720
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020001732A MX2020001732A (es) | 2017-08-31 | 2018-08-30 | Tratamiento de las afecciones del sistema nervioso central. |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US11285139B2 (enExample) |
| EP (1) | EP3675852A1 (enExample) |
| JP (2) | JP7196157B2 (enExample) |
| KR (1) | KR102680786B1 (enExample) |
| CN (2) | CN111065394B (enExample) |
| MX (1) | MX2020001732A (enExample) |
| WO (1) | WO2019045121A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4717314A2 (en) | 2011-10-14 | 2026-04-01 | Sage Therapeutics, LLC | 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof |
| WO2014169836A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor neuroactive steroids and methods of use thereof |
| SMT202100509T1 (it) | 2013-04-17 | 2021-11-12 | Sage Therapeutics Inc | Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia |
| CN117304245A (zh) | 2013-04-17 | 2023-12-29 | 萨奇治疗股份有限公司 | 刺激神经活性的19-去甲类固醇及其使用方法 |
| US9725481B2 (en) | 2013-04-17 | 2017-08-08 | Sage Therapeutics, Inc. | 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof |
| CA2918735C (en) | 2013-07-19 | 2023-08-01 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| CN105579043B (zh) | 2013-08-23 | 2021-09-14 | 萨奇治疗股份有限公司 | 神经活性类固醇、组合物和其用途 |
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| MY190408A (en) | 2014-10-16 | 2022-04-21 | Sage Therapeutics Inc | Compositions and methods for treating cns disorders |
| US20170233433A1 (en) | 2014-10-16 | 2017-08-17 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| WO2016082789A1 (en) | 2014-11-27 | 2016-06-02 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| LT3250210T (lt) | 2015-01-26 | 2021-04-12 | Sage Therapeutics, Inc. | Kompozicijos ir būdai, skirti gydyti cns sutrikimus |
| DK3258939T3 (da) | 2015-02-20 | 2022-12-12 | Sage Therapeutics Inc | Neuroaktive steroider, sammensætninger og anvendelser heraf |
| WO2018013613A1 (en) | 2016-07-11 | 2018-01-18 | Sage Therapeutics, Inc. | C17, c20, and c21 substituted neuroactive steroids and their methods of use |
| CA3030420C (en) | 2016-07-11 | 2025-11-18 | Sage Therapeutics, Inc. | C7, C12 AND C16 SUBSTITUTED NEUROACTIVE STEROIDS AND ASSOCIATED METHODS OF USE |
| TW202604538A (zh) | 2016-08-23 | 2026-02-01 | 美商賽吉醫療公司 | 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇 |
| CN111432812A (zh) | 2017-11-14 | 2020-07-17 | 爱思开生物制药株式会社 | 用于预防、减轻或治疗失神发作或显示失神发作的癫痫的氨基甲酸酯化合物的用途 |
| WO2020021372A1 (en) * | 2018-07-24 | 2020-01-30 | Zenvision Pharma Llp | Nasal drug delivery system of brivaracetam or salt thereof thereof |
| GB2580881A (en) * | 2018-11-30 | 2020-08-05 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| JP7670626B2 (ja) | 2019-05-31 | 2025-04-30 | セージ セラピューティクス， インコーポレイテッド | 神経刺激性ステロイド及びその組成物 |
| CN114746408B (zh) * | 2019-12-02 | 2025-02-14 | 豪夫迈·罗氏有限公司 | 炔基-(杂芳基)-甲酰胺hcn1抑制剂 |
| GB2597312A (en) * | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
| GB2597311A (en) * | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
| GB2597285A (en) | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
| US20240197704A1 (en) * | 2021-04-09 | 2024-06-20 | Johns Hopkins University | Treatment methods and compositions comprising perampanel |
| CN115487144A (zh) * | 2021-06-18 | 2022-12-20 | 北京万全德众医药生物技术有限公司 | 一种卢非酰胺的口服液制备方法 |
| WO2023175591A1 (en) * | 2022-03-18 | 2023-09-21 | Takeda Pharmaceutical Company Limited | Methods of treating neurological diseases |
| WO2024100531A1 (en) * | 2022-11-07 | 2024-05-16 | Takeda Pharmaceutical Company Limited | Method of treating seizure disorders |
| WO2025126159A1 (en) * | 2023-12-15 | 2025-06-19 | Takeda Pharmaceutical Company Limited | A method for treating a neurological disease in a recreational drug user |
| WO2025257799A1 (en) * | 2024-06-14 | 2025-12-18 | Takeda Pharmaceutical Company Limited | Methods of treating dravet syndrome |
| CN121550436B (zh) * | 2026-01-23 | 2026-05-12 | 四川大学华西医院 | 组合物及联合用药方式 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8648079B2 (en) | 2011-10-07 | 2014-02-11 | Takeda Pharmaceutical Company Limited | Heterocyclic compounds |
| EA029056B1 (ru) | 2012-12-11 | 2018-02-28 | Такеда Фармасьютикал Компани Лимитед | Гетероциклическое соединение |
| WO2014163161A1 (ja) | 2013-04-04 | 2014-10-09 | 武田薬品工業株式会社 | 複素環化合物 |
| JP6807322B2 (ja) | 2015-10-16 | 2021-01-06 | 武田薬品工業株式会社 | 複素環化合物の製造方法 |
-
2018
- 2018-08-30 US US16/642,153 patent/US11285139B2/en active Active
- 2018-08-30 MX MX2020001732A patent/MX2020001732A/es unknown
- 2018-08-30 EP EP18782213.5A patent/EP3675852A1/en active Pending
- 2018-08-30 CN CN201880055307.8A patent/CN111065394B/zh active Active
- 2018-08-30 CN CN202310328785.4A patent/CN116370475A/zh active Pending
- 2018-08-30 JP JP2020511399A patent/JP7196157B2/ja active Active
- 2018-08-30 WO PCT/JP2018/032949 patent/WO2019045121A1/en not_active Ceased
- 2018-08-30 KR KR1020207004753A patent/KR102680786B1/ko active Active
-
2022
- 2022-02-16 US US17/673,072 patent/US20220168294A1/en not_active Abandoned
- 2022-08-23 US US17/893,905 patent/US20230087903A1/en not_active Abandoned
- 2022-12-14 JP JP2022199076A patent/JP7469445B2/ja active Active
-
2024
- 2024-09-13 US US18/885,342 patent/US20250281477A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN111065394A (zh) | 2020-04-24 |
| US20220168294A1 (en) | 2022-06-02 |
| CA3073925A1 (en) | 2019-03-07 |
| WO2019045121A1 (en) | 2019-03-07 |
| JP7196157B2 (ja) | 2022-12-26 |
| CN116370475A (zh) | 2023-07-04 |
| JP2023027267A (ja) | 2023-03-01 |
| US11285139B2 (en) | 2022-03-29 |
| JP2020532508A (ja) | 2020-11-12 |
| CN111065394B (zh) | 2023-03-31 |
| EP3675852A1 (en) | 2020-07-08 |
| US20250281477A1 (en) | 2025-09-11 |
| US20230087903A1 (en) | 2023-03-23 |
| KR20200046022A (ko) | 2020-05-06 |
| KR102680786B1 (ko) | 2024-07-02 |
| JP7469445B2 (ja) | 2024-04-16 |
| US20200306238A1 (en) | 2020-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2023000095A1 (es) | Métodos de uso de inhibidores de ehmt2 para tratar o prevenir trastornos sanguíneos | |
| ECSP22023220A (es) | Derivados de indol mono o disustituidos como inhibidores de la replicación viral del dengue | |
| CO2019001625A2 (es) | Compuestos de captura de aldehído y usos de los mismos | |
| MX2017010982A (es) | Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer. | |
| CR20190468A (es) | Métodos para tratar enfermedades y trastornos mediados por completo | |
| ECSP18073293A (es) | Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue | |
| MX2016000364A (es) | Metodos para tratar o prevenir afecciones oftalmologicas. | |
| PE20190338A1 (es) | Metodos de tratamiento de trastornos del desarrollo con gaboxadol | |
| CL2017001822A1 (es) | Derivados de indol mono o disustituido como inhibidores de la replicación del virus del dengue | |
| AR101740A1 (es) | Terapia de combinación y composiciones | |
| CR20180495A (es) | Deribados de indol sustituidos como inhibidores de replicación viral del dengue | |
| MX2022007221A (es) | Compuestos y composiciones para el tratamiento o prevencion de trastornos patologicos asociados con exceso de deposicion de fibrina y/o formacion de trombos. | |
| CL2021000030A1 (es) | Uso de estimuladores de la sgc para el tratamiento de trastornos mitocondriales | |
| MX389545B (es) | Compuestos terapeuticos y composiciones para el tratamiento de trastornos sociales y trastornos de uso de sustancias. | |
| MX2018003023A (es) | Metodos de tratamiento de trastornos neurodegenerativos en una poblacion de pacientes particular. | |
| UY37466A (es) | N-hidroxiamidinheterociclos sustituidos como moduladores de la indolamina 2,3-dioxigenasa | |
| AR092103A1 (es) | Laquinimod en el tratamiento de los trastornos mediados por el receptor de canabinoides del tipo 1 (cb1) | |
| MX2016010085A (es) | Metodos para tratar lesion del cerebro leve. | |
| CL2021000743A1 (es) | Métodos para tratar trastornos mieloproliferativos | |
| MX2022003945A (es) | Metodo para tratar vih con cabotegravir y rilpivirina. | |
| MX2021006915A (es) | Inhibidores de cxcr7 para el tratamiento de cancer. | |
| ES3063390T3 (en) | Compositions and methods for treating inflammatory neurological disorders | |
| AR099416A1 (es) | Terapia combinada para la hipertensión resistente | |
| MX2018001684A (es) | Metodo de curacion de heridas. | |
| MX2017003140A (es) | Tratamiento de los sintomas asociados a terapia privacion de androgenos. |